NL8100720A - Derivaat van 2-<4-isobutylfenyl>-propionzuur; farmaceutisch preparaat; werkwijze voor de bereiding van het derivaat. - Google Patents
Derivaat van 2-<4-isobutylfenyl>-propionzuur; farmaceutisch preparaat; werkwijze voor de bereiding van het derivaat. Download PDFInfo
- Publication number
- NL8100720A NL8100720A NL8100720A NL8100720A NL8100720A NL 8100720 A NL8100720 A NL 8100720A NL 8100720 A NL8100720 A NL 8100720A NL 8100720 A NL8100720 A NL 8100720A NL 8100720 A NL8100720 A NL 8100720A
- Authority
- NL
- Netherlands
- Prior art keywords
- isobutylphenyl
- derivative
- propionic acid
- activity
- formula
- Prior art date
Links
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 title claims description 13
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 6
- 238000000034 method Methods 0.000 title description 11
- 230000000694 effects Effects 0.000 claims description 9
- 230000003356 anti-rheumatic effect Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 150000003751 zinc Chemical class 0.000 claims description 6
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 230000000767 anti-ulcer Effects 0.000 claims description 4
- 239000002798 polar solvent Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 13
- 239000011701 zinc Substances 0.000 description 13
- 239000002253 acid Substances 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 9
- 229910052725 zinc Inorganic materials 0.000 description 9
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 7
- 208000025865 Ulcer Diseases 0.000 description 7
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- 230000002467 anti-pepsin effect Effects 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003435 antirheumatic agent Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- -1 4-isobutylphenyl Chemical group 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000010470 Ageusia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical class [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940124056 Histamine H1 receptor antagonist Drugs 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 206010020989 Hypogeusia Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FPBPLBWLMYGIQR-UHFFFAOYSA-N Metiamide Chemical compound CNC(=S)NCCSCC=1N=CNC=1C FPBPLBWLMYGIQR-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 206010000596 acrodermatitis enteropathica Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Chemical class 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 235000019570 hypogeusia Nutrition 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229950003251 metiamide Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES488563*A ES488563A0 (es) | 1980-02-14 | 1980-02-14 | Procedimiento para la preparacion de un nuevo deriun aparato mejorado para manipular una banda continua. vado del acido 2-(4-isobutilfenil)-propionico |
| ES488563 | 1980-02-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8100720A true NL8100720A (nl) | 1981-09-16 |
Family
ID=8479811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8100720A NL8100720A (nl) | 1980-02-14 | 1981-02-13 | Derivaat van 2-<4-isobutylfenyl>-propionzuur; farmaceutisch preparaat; werkwijze voor de bereiding van het derivaat. |
Country Status (8)
| Country | Link |
|---|---|
| KR (1) | KR830005094A (member.php) |
| BE (1) | BE887469A (member.php) |
| CH (1) | CH646132A5 (member.php) |
| DE (1) | DE3105357C2 (member.php) |
| ES (1) | ES488563A0 (member.php) |
| FR (1) | FR2476069A1 (member.php) |
| IT (1) | IT1146741B (member.php) |
| NL (1) | NL8100720A (member.php) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3938227C1 (en) * | 1989-11-17 | 1991-05-02 | Dolorgiet Gmbh & Co Kg, 5205 St Augustin, De | Oral antiinflammatory and analgetic pharmaceutical compsn. - comprises magnesium ibuprofen dissolved in mixt. of water, propane-1,2-diol and glycerol |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1059677B (it) * | 1974-03-22 | 1982-06-21 | Neopharmed Spa | Sale di lisina ad azione terapeutica |
-
1980
- 1980-02-14 ES ES488563*A patent/ES488563A0/es active Granted
-
1981
- 1981-02-06 IT IT67171/81A patent/IT1146741B/it active
- 1981-02-11 BE BE0/203763A patent/BE887469A/fr not_active IP Right Cessation
- 1981-02-13 FR FR8103240A patent/FR2476069A1/fr active Granted
- 1981-02-13 DE DE3105357A patent/DE3105357C2/de not_active Expired
- 1981-02-13 CH CH96581A patent/CH646132A5/fr not_active IP Right Cessation
- 1981-02-13 NL NL8100720A patent/NL8100720A/nl not_active Application Discontinuation
- 1981-02-14 KR KR1019810000461A patent/KR830005094A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE3105357A1 (de) | 1982-01-14 |
| FR2476069A1 (fr) | 1981-08-21 |
| DE3105357C2 (de) | 1983-09-01 |
| ES8101534A1 (es) | 1980-12-16 |
| FR2476069B1 (member.php) | 1983-05-06 |
| IT8167171A0 (it) | 1981-02-06 |
| ES488563A0 (es) | 1980-12-16 |
| KR830005094A (ko) | 1983-07-23 |
| BE887469A (fr) | 1981-06-01 |
| CH646132A5 (fr) | 1984-11-15 |
| IT1146741B (it) | 1986-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3793457A (en) | Therapeutically active phenylalkane derivatives | |
| US3385886A (en) | Phenyl propionic acids | |
| US3883653A (en) | Method of preventing asthmatic symptoms | |
| US3558640A (en) | Certain pyridyl and thiazolyl methylthiopropionic acids and derivatives | |
| FR2499406A1 (fr) | Medicaments a base de nouveaux derives de la furo-(3,4-c)-pyridine | |
| JPS6247875B2 (member.php) | ||
| LU85634A1 (fr) | Nouveaux derives de la carboxymethoxy-7 furo-(3,4-c)-pyridine,leur preparation et compositions therapeutiques a base de ces composes | |
| US3766263A (en) | Substituted 2-phenoxyphenylacetic acids | |
| US3452081A (en) | Phenoxy substituted 2-alkenoic acids | |
| US3966966A (en) | Pharmaceutical compositions and method of treatment employing 1,3-dioxo-2,2-disubstituted indanyloxy alkanoic acids | |
| NL8100720A (nl) | Derivaat van 2-<4-isobutylfenyl>-propionzuur; farmaceutisch preparaat; werkwijze voor de bereiding van het derivaat. | |
| CA1050983A (en) | Amino derivatives of pyrido(2,3-b) pyrazine carboxylic acids and esters | |
| EP0172058A1 (fr) | Nouvelles phényl-naphthyridines, leur procédé de préparation, médicaments les contenant, notamment anti-ulcères | |
| US4648996A (en) | Phenyl substituted-2,4,6,8-nonatetraenoic acid | |
| US4036983A (en) | Ferrocene compounds and pharmaceutical composition for use in treatment of iron deficiency in an animal | |
| US4304788A (en) | Hydroxyalkanoic acid derivatives | |
| US3506658A (en) | 2-(10-methyl-2-phenoxazinyl)propionic acid | |
| HU195480B (en) | Process for preparing phenyl nonatetraenic acid derivatives | |
| US3870751A (en) | Substituted phenyl acetic acids | |
| US3933835A (en) | New aliphatically substituted aryl-chalcogeno-hydrocarbon derivatives | |
| CH628014A5 (en) | Gamma-aryl-gamma-oxoisovaleric acids having antiphlogistic and antalgic properties | |
| US3845215A (en) | Phenylalkane derivatives in the treatment of inflammation | |
| EP0094422A1 (en) | SUBSTITUTED PYRIDINE. | |
| US4894480A (en) | Phenyl substituted-2,4,6,8-nonatetraenoic acid | |
| US4511576A (en) | Antidiabetic pyrrolecarboxylic acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| BV | The patent application has lapsed |